NASDAQ:IOVA News

Stocks

Headlines

Mid-Cap Healthcare Stocks Promising Growth for Investors

Mid-Cap Healthcare Stocks Show Potential Gains. Several mid-cap healthcare stocks are gaining attention for their growth prospects and modest valuations, making them attractive options for long-term investors.

Date: 
AI Rating:   6

Investment Potential in Mid-Cap Healthcare Stocks

Investors are often drawn to mid-cap stocks with modest valuations that have potential for substantial returns. This report highlights three mid-cap healthcare stocks—Iovance Biotherapeutics, CRISPR Therapeutics, and Viking Therapeutics—that may see significant growth.

Iovance Biotherapeutics (NASDAQ: IOVA) has a market cap of $2.3 billion and recently received FDA accelerated approval for its cell therapy, Amtagvi. This approval allows for the possibility of generating $1 billion in annual sales, depending on further approvals and market rollout. The company has reduced its net losses from $113.8 million to $83.5 million. This improvement indicates a potential for strong future performance, particularly if it can continue to mitigate losses and deliver promising clinical trial results.

CRISPR Therapeutics (NASDAQ: CRSP), valued at $3.6 billion, has faced challenges, seeing a 37% decline over the past year. Despite obtaining key approvals for its gene therapy treatment, Casgevy, the company has reported a net loss of $240 million over the last 12 months. However, Casgevy has a high price point of $2.2 million, which could significantly enhance CRISPR’s profitability if the therapy gains insurance coverage. Investors are hopeful for future financial improvements.

Viking Therapeutics (NASDAQ: VKTX) is currently valued at $4.7 billion and has seen substantial growth due to its weight loss drug, VK2735. Although it does not have an approved product yet, the potential market for obesity drugs is significant, valued at $200 billion. If the drug achieves regulatory approval, it could lead to explosive stock growth, with investors optimistic about the company’s prospects.